Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 56, Issue 6, 2013, Pages 334-337

  Simonsson, Roger ^a   Stenhagen, Gunnar ^a   Ericsson, Cecilia ^a   Elmore, Charles S ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

ethylmelagatran; Hydrogen isotope exchange; hydroxymelagatran; melagatran; N heterocyclic carbene; ximelagatran

Indexed keywords

CATALYSTS; HYDROGEN; ORGANIC COMPOUNDS; SYNTHESIS (CHEMICAL);

ETHYLMELAGATRAN; HYDROGEN ISOTOPE EXCHANGE; HYDROXYMELAGATRAN; LIVER TOXICITY; MELAGATRAN; N-HETEROCYCLIC; N-HETEROCYCLIC CARBENES; TARGET COMPOUND; XIMELAGATRAN; ]+ CATALYST;

TRITIUM;

ETHYLMELAGATRAN; HYDROGEN; HYDROXYLAMINE; HYDROXYMELAGATRAN; MELAGATRAN; THROMBIN INHIBITOR; TRITIUM; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTICLE; CATALYST; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; ISOTOPE LABELING; LIVER TOXICITY; RADIOCHEMISTRY; REDUCTION; STOICHIOMETRY;

ETHYLMELAGATRAN; HYDROGEN-ISOTOPE EXCHANGE; HYDROXYMELAGATRAN; MELAGATRAN; N-HETEROCYCLIC CARBENE; XIMELAGATRAN;

AMIDINES; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; ISOTOPE LABELING; TRITIUM;

EID: 84879154054     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.3028     Document Type: Article

References (11)

1. J. Hirsh, New England Journal of Medicine 1991; 324, 1865-1875.
2. J. Hirsh, M. O'Donnell, J. W. Eikelboom, Circulation 2007; 116, 552-560.
3. D. Gustafsson, J. Nyström, S. Carlsson, U. Bredberg, U. Eriksson, E. Gyzander, M. Elg, T. Antonsson, K. Hoffmann, A. Ungell, H. Sörensen, S. Någård, A. Abrahamsson, R. Bylund, Thrombosis Research 2001; 101, 181.
4. U. G. Eriksson, U. Bredberg, K. Hoffmann, A. thuresson, M. Gabrielsson, H. Ericsson, M. Ahnoff, K. Gislen, G. Fager, D. Gustafsson, Drug Metabolism and Disposition 2003; 294, 294-305.
5. Kindmark, A., Jawaid, A., Harbron, C.G., B. J. Barratt, O. F. Bengtsson, T. B. Andersson, S. C. Carlsson, K. E. Cederbrant, N. J. Gibson, M. Armstrong, M. E. L. Lagerström-Fermér, A. Dellsén, E. M. Brown, M. Thornton, C. Dukes, S. C. Jenkins, M. A. Firth, G. O. Harrod, T. H. Pinel, S. M. E. Billing-Clason, L. R. Cardon, R. E. March, Pharmacogenomics Journal 2008; 8, 186-195.
6. U. Andersson, J. Lindberg, S. Wang, R. Balasubramanian, M. Marcusson-Ståhl, M. Hannula, C. Zeng, P. J. Juhasz, J. Kolmert, J. Bäckström, L. Nord, K. Nilsson, S. Martin, B. Glinghammar, K. Cederbrant, I. ISchuppe-Koistinen, Biomarkers 2009; 14, 572-586.
7. P. T. Illing, J. P. Vivian, N. L. Dudek, L. Kostenko, Z. Chen, M. Bharadwaj, J. J. Miles, l. Kjer-Nielsen, S. Gras, N. A. Williamson, S. R. Burrows, A. W. Purcell, J. Rossjohn, J. James McCluskey, nature 2012; 486, 554-558.
8. M. Keisu, T. B. Andersson, in Drug induced liver injury in human: The case of ximelagatran, (Ed: E. Uetrecht), Springer-Verlag, Berlin Heidelberg, 2010, pp. 407-418.
9. R. H. Crabtree, Acc. Chem. Res. 1979; 12, 331.
10. D. Hesk, P. R. Das, B. Evans, J. Labelled Compd,. Radiopharmaceut. 1995; 36, 497-502.
11. J. A. Brown, S. Irvine, A. R. Kennedy, W. J. Kerr, S. Andersson, G. N. Nilsson, Chem. Comm. 2008; 1115.